# US 2002/0119533 A1 · Amplification primer pairs and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0119533 A1
- Document ID: US20020119533A1
- Status: Published application
- Kind: A1
- Application number: 09/932,129
- Filed: 2001-08-16
- Published: 2002-08-29
- Earliest claimed: 1999-04-08
- Inventors: Bob D. Brown
- Web page: https://patentgrep.com/patent/US20020119533A1

## CPC

- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 2521/107: RNA dependent DNA polymerase,(i.e. reverse transcriptase)
- C12Q 2531/113: PCR
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Amplification primer pairs comprising an oligonucleotide anchor and primer. The anchor has a nucleic acid chemistry which is not a substrate for reverse transcriptases and DNA polymerases, and a 3′-end which is not capable of priming DNA synthesis. The primer has a nucleic acid chemistry that is a substrate for reverse transcriptases and DNA polymerases. The anchor and the primer each include regions of nucleotide complementarity which are capable of associating with each other to form a stem structure. The stem structure includes a nucleotide sequence which is complementary to a universal primer. One primer pair (reverse pair) is used for first strand synthesis, while the second primer pair (forward pair) is used for second strand synthesis. The universal primers sustain the amplification reaction and produce the majority of the final product.

## Claims

### Claim 1

An amplification primer pair comprising an oligonucleotide anchor and primer, said anchor having a nucleic acid chemistry which is not a substrate for reverse transcriptases or DNA polymerases, and/or having a 3′-end which is not capable of priming nucleic acid synthesis;
wherein said primer has a nucleic acid chemistry that is a substrate for reverse transcriptases or DNA polymerases; and
wherein said anchor and said primer each include a region of complementary nucleotides which readily associate with each other to form a stem structure in the absence of a target nucleic acid, wherein the stem structure includes a region which is complementary to a universal primer.

### Claim 2 (depends on 1)

The primer pair of claim 1, wherein said anchor sequence and said stem regions are connected by a flexible linker.

### Claim 3 (depends on 2)

The primer pair of claim 2, wherein said flexible linker is selected from the group consisting of polyethylene glycol, polypropylene glycol, polyethylene, polypropylene, polyamides and polyesters.

### Claim 4 (depends on 1)

The primer pair of claim 1, wherein said primer comprises a tail region which extends beyond the length of said stem region of said anchor.

### Claim 5 (depends on 1)

The primer pair of claim 1, wherein said primer comprises one or more modified bases.

### Claim 6 (depends on 1)

The primer pair of claim 1, wherein said anchor comprises one or more modified backbone linkages.

### Claim 7 (depends on 1)

The primer pair of claim 1, wherein said anchor and said primer are each between 6 and 24 bases in length.

### Claim 8 (depends on 1)

The primer pair of claim 1, further in association with a universal primer which is complementary to a region of said stem structure.

### Claim 9

A sequencing primer pair comprising an oligonucleotide anchor and primer, said anchor having a nucleic acid chemistry which is not a substrate for reverse transcriptases or DNA polymerases, and/or having a 3′-end which is not capable of priming nucleic acid synthesis;
wherein said primer has a nucleic acid chemistry that is a substrate for reverse transcriptases or DNA polymerases; and
wherein said anchor and said primer each include a region of complementary nucleotides which readily associate with each other to form a stem structure in the absence of a target nucleic acid.

### Claim 10 (depends on 9)

The primer pair of claim 9, wherein said stem structure includes a region which is complementary to a universal primer.

### Claim 11 (depends on 10)

The primer pair of claim 10, wherein said anchor sequence and said stem region are connected by a flexible linker.

### Claim 12 (depends on 11)

The primer pair of claim 11, wherein said flexible linker is selected from the group consisting of polyethylene glycol, polypropylene glycol, polyethylene, polypropylene, polyamides and polyesters.

### Claim 13 (depends on 10)

The primer pair of claim 10, wherein said primer comprises a tail region which extends beyond the length of said stem region of said anchor.

### Claim 14 (depends on 9)

The primer pair of claim 9, wherein said primer comprises one or more modified bases.

### Claim 15 (depends on 9)

The primer pair of claim 9, wherein said anchor comprises one or more modified backbone linkages.

### Claim 16 (depends on 9)

The primer pair of claim 9, wherein said anchor and said primer are each between 6 and 24 bases in length.

### Claim 17 (depends on 9)

The primer pair of claim 9, further in association with a universal primer which is complementary to a region of said stem structure.

### Claim 18

A method for amplifying a target nucleic acid sequence, comprising the steps of: combining said target nucleic acid sequence a forward anchor (FA), forward primer (FP), reverse anchor (RA), reverse primer (RP), forward universal primer (FUP) and reverse universal primer (RUP), wherein said FA/FP readily associate to form a first primer pair and said RA/RP readily associate to form a second primer pair via association of their complementary stem regions in the absence of said target nucleic acid, wherein said FUP is complementary to the FA/FP stem region, and wherein said RUP is complementary to the RA/RP stem region wherein said primer pairs are selected on the basis of complementarity to said target nucleic acid sequence to flank said target nucleic acid sequence; and
amplifying said nucleic acid sequence via enzyme-mediated amplification.

### Claim 19 (depends on 18)

The method of claim 18, wherein said nucleic acid sequence encodes a therapeutic gene product.

### Claim 20 (depends on 18)

The method of claim 18, wherein said nucleic acid sequence is DNA or RNA.

### Claim 21 (depends on 18)

The method of claim 18, wherein said enzyme-mediated amplification is PCR amplification.
